NCT05129241View on ClinicalTrials.gov

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

CompletedOBSERVATIONAL

Enrollment

163

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions

Primary Hypercholesterolaemia and Mixed DyslipidaemiaAtherosclerotic Cardiovascular Disease

Trial Locations (1)

Unknown

Investigational Site Number, Germany

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY